Dwight Owen(@dwightowenmd) 's Twitter Profile Photo

Dr. Angel Qin discusses targeted perioperative therapies in . Lots of new agents building on success in EGFR and ALK studies to date.

Dr. @AngelQinMD discusses targeted perioperative therapies in #nsclc . Lots of new agents building on success in EGFR and ALK studies to date.  #TTLC24
account_circle
Urs Weber MD(@UrsWeberMD) 's Twitter Profile Photo

Had a great time discussing our work looking at outcomes in patients with exon 19 deletion or L858R mutated post-progression on osimertinib by mechanism of resistance at the poster session!

Had a great time discussing our work looking at outcomes in patients with #EGFR exon 19 deletion or L858R mutated #lungcancer post-progression on osimertinib by mechanism of resistance at the #TTLC24 poster session!
account_circle
Allison Chang(@aebchang) 's Twitter Profile Photo

A nuanced + thoughtful discussion by JessicaJLinMD re: what can/can’t be generalized from adjuvant TKI trials—can ADAURA/ALINA be extended to other oncogene-driven NSCLC? Conceptually, yes. But we need more work to delineate specific tox profiles to best counsel our pts.

A nuanced + thoughtful discussion by @JessicaJLinMD re: what can/can’t be generalized from adjuvant TKI trials—can ADAURA/ALINA be extended to other oncogene-driven NSCLC? Conceptually, yes. But we need more work to delineate specific tox profiles to best counsel our pts. #TTLC24
account_circle
PeerView(@PeerView) 's Twitter Profile Photo

Improve your identification of patients with eligible to receive across the disease continuum in this new video from —featuring Sandip Patel, MD (Sandip Patel MD), Tina Cascone, MD, PhD & John V. Heymach, MD, PhD! bit.ly/48ImRrc

account_circle
Joshua Reuss(@Joshua_Reuss) 's Twitter Profile Photo

Dr. Antoinette Wozniak with an EXCELLENT discussion of the exploding peri-operative space in resectable NSCLC at IASLC Best of webinar. What will push us toward neoadj vs perioperative? pCR? MRD? impt research questions that need answering.

Dr. Antoinette Wozniak with an EXCELLENT discussion of the exploding peri-operative space in resectable NSCLC at @IASLC  Best of #TTLC24 webinar. What will push us toward neoadj vs perioperative? pCR? MRD? impt research questions that need answering.
account_circle
Monica Chen(@MonicaChenMD) 's Twitter Profile Photo

Great to present today at the IASLC meeting on a huge team effort to find better treatments for patients with metastatic EGFR/TP53/RB1 lung cancer in the city I grew up in. Memorial Sloan Kettering Cancer Center EGFR Resisters Helena Yu

account_circle
Chul Kim(@chulkimMD) 's Twitter Profile Photo

The pace of drug development for ALK-fusion positive NSCLC has been one of the fastest. Prelim results of NVL-655, 4th gen ALK TKI, are promising. What characteristics should a hypothetical 5G agent have? Fascinating talk by Dr. Misako Nagasaka

The pace of drug development for ALK-fusion positive NSCLC has been one of the fastest. Prelim results of NVL-655, 4th gen ALK TKI, are promising. What characteristics should a hypothetical 5G agent have? Fascinating talk by Dr. @MNagasaka #TTLC24
account_circle
Meera Ragavan, MD MPH(@meera_ragavan) 's Twitter Profile Photo

Interesting and much-needed efforts by ⁦National Cancer Institute⁩ to modernize clinical trials presented by Dr. Prindiville at - 1.make data collection less onerous, 2.increase workforce diversity, 3.implement virtual programs to mitigate staffing shortages

Interesting and much-needed efforts by ⁦@theNCI⁩ to modernize clinical trials presented by Dr. Prindiville at #TTLC24- 1.make data collection less onerous, 2.increase workforce diversity, 3.implement virtual programs to mitigate staffing shortages
account_circle